title: Clinical effects of recent cocaine use on patients with acute schizophrenia.
abstract: OBJECTIVE
  Dopamine function has been hypothesized to be involved in both producing schizophrenic symptoms and mediating cocaine's reinforcing properties. As a result, cocaine abuse in schizophrenic patients may be seen as a natural experiment that may alter the phenomenology and neurobiology of schizophrenia. This report concerns the clinical effects of cocaine abuse and cessation in schizophrenic patients at two times: when patients presented to the psychiatric emergency service and again after 4 weeks of hospitalization.
  
  
  METHODS
  The subjects were 15 cocaine-abusing and 22 cocaine-abstaining schizophrenic patients. Diagnostic assessments were performed with the Structured Clinical Interview for DSM-III-R--Patient Version, which uses DSM-III-R criteria. All of the patients were assessed at both times with the Brief Psychiatric Rating Scale, the Scale for the Assessment of Positive Symptoms, and the Scale for the Assessment of Negative Symptoms.
  
  
  RESULTS
  Cocaine-abusing schizophrenic patients showed fewer negative signs and more anxiety/depression at the hospital-admission assessment than their nonabusing counterparts. At retest, no group differences were detected in patients' negative signs or mood symptoms. Severity of positive symptoms was equal at both testing sessions.
  
  
  CONCLUSIONS
  The significant difference in negative signs and mood symptoms at admission assessment was attributed to the neurobiological impact of cocaine. The role of psychostimulants in schizophrenic patients is discussed.
authors.affiliation: New York University School of Medicine, NY, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Serper
authors.forename: M
authors.initials: M
authors.lastname: Alpert
authors.forename: N A
authors.initials: NA
authors.lastname: Richardson
authors.forename: S
authors.initials: S
authors.lastname: Dickson
authors.forename: M H
authors.initials: MH
authors.lastname: Allen
authors.forename: A
authors.initials: A
authors.lastname: Werner
mesh_terms: D000208:Acute Disease; D000328:Adult; D000339:Affect / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000494:pharmacology / Q000627:therapeutic use; D003042:Cocaine / Q000494:pharmacology; D015897:Comorbidity; D017831:Diagnosis, Dual (Psychiatry); D004637:Emergency Services, Psychiatric; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D012565:Schizophrenic Psychology; D012651:Self Medication; D012720:Severity of Illness Index; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology*
chemical_list: D000697:Central Nervous System Stimulants; D003042:Cocaine